system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
Exhibit 10.2 INTELLECTUAL PROPERTY AGREEMENT This Intellectual Property Agreement (this "Agreement") is entered into on May 12, 2020 ("Effective Date"), concerning the pursuits set forth herein for the collective development, implementation and commercialization of a potential treatment for the COVID-19 virus and its effects on the human body (collectively referred to herein as the "Joint Venture") by and between: Marv Enterprises, LLC, a Limited Liability Company organized under the laws of the Commonwealth of Pennsylvania ("Marv"), Premier Biomedical, Inc. (OTC Pink: BIEI), a Nevada corporation ("Premier"), Technology Health, Inc. (OTC Pink: HALB), a Colorado corporation f/k/a Halberd Corporation ("THI"), Each shall be referred to as a "Party" and collectively as the "Parties." RECITALS: WHEREAS, Marv is a single member LLC with Dr. Mitchell Felder as the sole member. WHEREAS, Premier is publicly traded on the Pink Sheets, trading symbol BIEI. WHEREAS, THI is publicly traded on the Pink Sheets, trading symbol HALB. WHEREAS, Marv is owner of U.S. Patent 9,216,386 and U.S. Patent 8,758,287 collectively referred to as the "Issued Patents". WHEREAS, Premier has an Exclusive License to the Issued Patents via an Agreement executed by Marv and Premier on May 12, 2010 ("2010 Agreement"). WHEREAS, Marv has subsequently filed numerous patent applications on subject matter related to the Issued Patents which are listed in Appendix A. WHEREAS, Marv and Premier expanded Premier's Exclusive License to include all the Applications listed in Appendix A via a Third Addendum to the 2010 Agreement executed by Marv and Premier on the Effective Date ("2020 Agreement"). WHEREAS, Marv has filed US provisional patent applications specifically related to methods of treatment for Covid-19 as starred in Appendix A (Covid-19 Applications) to which Premier has an exclusive license via the 2020 Agreement. WHEREAS, this Agreement contemplates the development of a methodology for the extracorporeal treatment of a patient's body fluid to treat Covid-19 (Field of Covid-19 Treatment). WHEREAS, the Parties are desirous of collaborating for the creation and distribution of products designed in the Field of Covid-19 Treatment (Covid-19 Licensed Products) WHEREAS, THI is desirous of exclusively licensing the Applications listed in Appendix A; WHEREAS, Premier is willing to assign its rights in the 2010 Agreement/2020 Agreement; WHEREAS, Marv in this Agreement gives its written consent for Premier to assign its rights in the 2010 Agreement/2020 Agreement to THI; NOW, THEREFORE, for good and adequate consideration, the receipt of which is hereby acknowledged, the Parties covenant, promise and agree as follows: 1 AGREEMENT 1. RECITALS. The Recitals are hereby incorporated herein by this reference, as if fully restated herein. 2. LICENSING. To the extent that terms in the 2010 Agreement/2020 Agreement are not contradicted or revised here, the terms as stated in 2010 Agreement/2020 Agreement remain in full effect, are controlling, and apply to THI licensing of the Applications in Appendix A and the Licensed Products derived therefrom. (a) License - THI is granted the following rights to the Applications in Appendix A and the Licensed Products derived therefrom: Scope. The licenses granted herein are exclusive worldwide licenses to: 1. make, have made, use, lease, sell and import Licensed Products for the legal purposes of researching, developing, manufacturing, assembling, distributing, and selling the Licensed Products; 2. make, have made, use and import machines, tools, materials and other instrumentalities, insofar as such machines, tools, materials and other instrumentalities are involved in or incidental to the research, development, manufacture, testing or repair of Licensed Products which are or have been made, used, leased, owned, sold or imported by the Licensee; and 3. convey to any customer of the Licensee, with respect to any Licensed Product which is sold or leased to such customer, rights to use and resell such Licensed Product as sold or leased by Licensee (whether or not as part of a larger combination); provided, however, that no rights may be conveyed to customers with respect to any Invention which is directed to (i) a combination of such Licensed Product (as sold or leased) with any other product, (ii) a method or process which is other than the inherent use of such Licensed Product itself (as sold or leased), or (iii) a method or process involving the use of a Licensed Product to manufacture (including associated testing) any other product. 4. Licenses granted herein are solely for products in the form sold by the Licensee and are not to be construed either (i) as consent by the Marv to any act which may be performed by the Licensee, except to the extent impacted by a
"""

Extract the exact clause related to "Document Name" from the excerpt above.

assistant: Intellectual Property Agreement